Results 21 to 30 of about 6,382,401 (301)

The use of automated quantitative analysis to evaluate epithelial-to-mesenchymal transition associated proteins in clear cell renal cell carcinoma [PDF]

, 2012
Background: Epithelial-to-mesenchymal transition (EMT) has recently been implicated in the initiation and progression of renal cell carcinoma (RCC). Some mRNA gene expression studies have suggested a link between the EMT phenotype and poorer clinical ...
Antony C P Riddick, Stewart Grant D., Faratian Dana, Theodoulou Marianna, Grant D Stewart, Dana Faratian (171110), O'Mahony Fiach C., O'Mahony, Fiach C, James Varley (181899), David J. Harrison (171106), Jyoti Nanda (181902), Riddick, Antony C P, Varley James, Marianna Theodoulou, Dana Faratian, Varley, James, Riddick Antony C. P., Harrison David J., Fiach C O'Mahony, Antony C. P. Riddick (145315), Jyoti Nanda, Harrison, David J, David J Harrison, O'Mahony, Fiach C., Faratian, Dana, Riddick, Antony C. P., Nanda Jyoti, Marianna Theodoulou (181905), Grant D. Stewart (145312), Theodoulou, Marianna, Nanda, Jyoti, Stewart, Grant D., James Varley, Stewart, Grant D, Fiach C. O'Mahony (181892), Harrison, David J., Harrison, David J.; id_orcid   +36 more
core   +3 more sources

Renal cell carcinoma [PDF]

Nature Reviews Disease Primers, 2017
Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and accounts for >90% of cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, of which clear cell RCC (ccRCC) is most common and accounts for most cancer-related deaths. Although somatic VHL mutations have been described for some time, more-
Hsieh, James J., Purdue, Mark P., Signoretti, Sabina, Swanton, Charles, Albiges, Laurence, Schmidinger, Manuela, Heng, Daniel Y., Larkin, James, Ficarra, Vincenzo   +8 more
openaire   +4 more sources

Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo [PDF]

, 2013
Targeted drugs have significantly improved the therapeutic options for advanced renal cell carcinoma (RCC). However, resistance often develops, negating the benefit of these agents.
Eva Juengel, Jasmina Makarević, Axel Haferkamp, Georg Bartsch, Roman A Blaheta, Jüngel, Eva, Nelson, Karen, Blaheta, Roman A., Igor Tsaur, Makarević, Jasmina, Karen Nelson, Tsaur, Igor, Haferkamp, Axel, Bartsch, Georg, Juengel Eva, Makarević Jasmina, Blaheta Roman A., Nelson Karen, Tsaur Igor, Haferkamp Axel, Bartsch Georg   +20 more
core   +2 more sources

Significance of chromosome 9p status in renal cell carcinoma:a systematic review and quality of the reported studies [PDF]

, 2014
Defining the prognosis of renal cell carcinoma (RCC) using genetic tests is an evolving area. The prognostic significance of 9p status in RCC, although described in the literature, remains underutilised in clinical practice. The study explored the causes
El-Mokadem, Ismail, Fitzpatrick, John, Cunningham, J., Nabi, Ghulam, Pratt, Norman, Fleming, Stewart, Rai, Bhavan   +6 more
core   +1 more source

Temsirolimus for patients with metastatic renal cell carcinoma : outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center [PDF]

, 2014
Aim: Temsirolimus has shown efficacy as first-line treatment of patients with metastatic renal cell carcinoma and poor prognostic features. The efficacy of temsirolimus in other clinical settings, such as second-line therapy, is unclear.
Pascoe, Jennifer, Afshar, Mehran, Porfiri, Emilio, Whitmarsh, Sue, James, Nicholas D.   +4 more
core   +1 more source

The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo [PDF]

, 2008
Histone deacetylase (HDAC) inhibitors represent a promising class of antineoplastic agents which affect tumour growth, differentiation and invasion. The effects of the HDAC inhibitor valproic acid (VPA) were tested in vitro and in vivo on pre-clinical ...
Eva Juengel, Mickuckyte, Ausra, Hudak, Lukasz, Jones, Jon, Lukasz Hudak, Jüngel, Eva, Dietger Jonas, Blaheta, Roman A., Roman A. Blaheta, Wedel, Steffen Alexander, Ausra Mickuckyte, Jonas, Dietger, Jon Jones, Steffen Wedel   +13 more
core   +1 more source

Expression of lactate dehydrogenase C correlates with poor prognosis in renal cell carcinoma

Tumor Biology, 2017
Lactate dehydrogenase C is an isoenzyme of lactate dehydrogenase and a member of the cancer–testis antigens family. In this study, we aimed to investigate the expression and functional role of lactate dehydrogenase C and its basic mechanisms in renal ...
Yibo Hua, Chao Liang, Jundong Zhu, Chenkui Miao, Yajie Yu, Aimin Xu, Jianzhong Zhang, Pu Li, Shuang Li, Meiling Bao, Jie Yang, Chao Qin, Zengjun Wang   +12 more
doaj   +1 more source

Case of hereditary papillary renal cell carcinoma [PDF]

Journal of Community Hospital Internal Medicine Perspectives, 2012
Renal cell carcinoma is the most common type of renal malignancy and it originates from the renal tubular epithelium. Due to the diversity in the histopathological and molecular characteristics, it is typically subclassified into five different ...
Sadaf Mustafa, Nima Jadidi, Sheila F. Faraj, Ronald Rodriguez   +3 more
doaj   +1 more source

UBE2QL1 is Disrupted by a Constitutional Translocation Associated with Renal Tumor Predisposition and is a Novel Candidate Renal Tumor Suppressor Gene [PDF]

, 2013
Investigation of rare familial forms of renal cell carcinoma (RCC) has led to the identification of genes such as VHL and MET that are also implicated in the pathogenesis of sporadic RCC. In order to identify a novel candidate renal tumor suppressor gene,
Hodgson, S, Morris, Mark R., Turnell, Andrew S., Woodward, ER, Prigmore, Elena, Woodward, Emma R.; id_orcid, Wake, NC, Wake, Naomi C., Gribble, Susan M., Ricketts, Christopher J., Skytte, AB, Brown, Michael, Banks, RE, Morris, MR, Prigmore, E, Maher, ER, Woodward, Emma R., Clarke, Noel, Hodgson, Shirley, Skytte, Anne-bine, Ricketts, CJ, Turnell, AS, Brown, Michael; id_orcid, Maher, Eamonn R., Clarke, N, Banks, Rosamonde E., Gribble, SM, Brown, M, Skytte, Anne Bine, Wake, N, Clarke, Noel W, Brown, Michael D, Ricketts, C, Woodward, E, Skytte, A-B, Maher, E, Morris, M, Banks, R, Turnell, A, Gribble, S   +39 more
core   +1 more source

Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways [PDF]

, 2013
The DNA-damaging agent camptothecin (CPT) and its analogs demonstrate clinical utility for the treatment of advanced solid tumors, and CPT-based nanopharmaceuticals are currently in clinical trials for advanced kidney cancer; however, little is known ...
Ashcroft, M, Carroll, VA, Selvarajah, J, Moumen, A, Nathawat, K   +4 more
core   +2 more sources